Is KZIA or LFVN more undervalued in 2026?

CirclFi compares Kazia Therapeutics Limited (KZIA) and Lifevantage Corporation (LFVN) using 13 institutional-grade valuation models. KZIA has a Quality of Company score of 4.3/10 while LFVN scores 9.0/10.

Which is a better buy — KZIA or LFVN?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do KZIA and LFVN valuations compare?

KZIA at $12.78 and LFVN at $7.87 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

KZIA vs LFVN Valuation Comparison 2026 — Intrinsic Value Analysis

KZIA

Pharmaceutical Preparations

Kazia Therapeutics Limited

Quality

4.3

out of 10

Value Trap

SAFE

Price

$12.78

Last close

Models

10/13

Active

LFVN

Pharmaceutical Preparations

Lifevantage Corporation

Quality

9.0

out of 10

Value Trap

SAFE

Price

$7.87

Last close

Models

13/13

Active

Model-by-Model Comparison

Model	Type	KZIA Fair Value	KZIA Upside	LFVN Fair Value	LFVN Upside
Bayesian DCF	Intrinsic	$5.81	-54.5%	$5.48	-30.3%
Earnings Power Value	Intrinsic	—	—	$2.86	-63.6%
EROIC Spread	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
Markov DDM	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
Dynamic NAV	Asset-Based	$2.95	-76.9%	$0.89	-88.7%
PWERM	Option-Based	$•••.••	••.•%	$•••.••	••.•%
Regime Cross-Sectional	Relative	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%
RCMH-DCF	Intrinsic	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for KZIA vs LFVN — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

KZIA vs LFVN — Which Stock Is More Undervalued?

LFVN scores higher with a 9.0/10 quality rating vs KZIA's 4.3/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Kazia Therapeutics Limited (KZIA) and Lifevantage Corporation (LFVN) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

KZIA currently trades at $12.78 with a QOC of 4.3/10, while LFVN trades at $7.87 with a QOC of 9.0/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).